Technical Analysis for DMTK - DermTech, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Historical DMTK trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Resistance | Bearish | 0.00% | |
| 20 DMA Resistance | Bearish | -2.07% | |
| NR7 | Range Contraction | -0.76% | |
| NR7-2 | Range Contraction | -0.76% | |
| Spinning Top | Other | -1.45% | |
| NR7 | Range Contraction | -1.45% | |
| 20 DMA Resistance | Bearish | -2.98% | |
| 180 Bearish Setup | Bearish Swing Setup | -2.98% | |
| 20 DMA Resistance | Bearish | -7.37% | |
| Oversold Stochastic | Weakness | -0.54% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Down 2 % | 3 days ago |
| Fell Below Previous Day's Low | 3 days ago |
| Down 1% | 3 days ago |
| Fell Below 10 DMA | 3 days ago |
| 10 DMA Support | 3 days ago |
Free Daily (Stock) Chart Reading
- Earnings date: 11/08/2021
DermTech, Inc. Description
DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive diagnostic tests to diagnosis skin cancer and related conditions in the United States. The company offers Pigmented Lesion Assay (PLA), a gene expression test that helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions. It also provides Nevome test, an adjunctive reflex test for the PLA; and adhesive skin sample collection kits, as well as gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways. The company is also developing non-melanoma skin cancer diagnostic and non-melanoma skin cancer risk assessment products. The company sells its products primarily to pathology and oncology practitioners. DermTech, Inc. is headquartered in La Jolla, California.
Classification
Sector: Industrials
Industry: Conglomerates
Keywords: Medicine Cancer Melanoma Gene Expression Dermatology Diagnostic Tests Risk Assessment Pathology Biopsy Assessment Products Skin Cancer Cutaneous Conditions Melanoma Skin Cancer Pigmented Lesion
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 84.49 |
| 52 Week Low | 11.25 |
| Average Volume | 374,191 |
| 200-Day Moving Average | 42.04 |
| 50-Day Moving Average | 34.48 |
| 20-Day Moving Average | 32.78 |
| 10-Day Moving Average | 31.79 |
| Average True Range | 1.88 |
| ADX | 16.26 |
| +DI | 15.19 |
| -DI | 18.55 |
| Chandelier Exit (Long, 3 ATRs) | 31.11 |
| Chandelier Exit (Short, 3 ATRs) | 35.85 |
| Upper Bollinger Bands | 35.86 |
| Lower Bollinger Band | 29.69 |
| Percent B (%b) | 0.26 |
| BandWidth | 18.81 |
| MACD Line | -0.94 |
| MACD Signal Line | -0.91 |
| MACD Histogram | -0.027 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 33.92 | ||||
| Resistance 3 (R3) | 34.18 | 33.56 | 33.48 | ||
| Resistance 2 (R2) | 33.56 | 32.89 | 33.43 | 33.33 | |
| Resistance 1 (R1) | 32.42 | 32.47 | 32.11 | 32.16 | 33.19 |
| Pivot Point | 31.80 | 31.80 | 31.64 | 31.67 | 31.80 |
| Support 1 (S1) | 30.66 | 31.13 | 30.35 | 30.40 | 29.37 |
| Support 2 (S2) | 30.04 | 30.71 | 29.91 | 29.23 | |
| Support 3 (S3) | 28.90 | 30.04 | 29.08 | ||
| Support 4 (S4) | 28.64 |
